Substance / Medication

Mitoxantrone

Overview

Active Ingredient
mitoxantrone
RxNorm CUI
7005

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Clinical Trials

9 trials linked to this intervention

9
Total Trials
3
Recruiting
1
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Effect of Dose Ratio on Mitoxantrone and Daunorubicin in Acute Myeloid Leukemia: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Deng Lei, Zhang Changjian, Ying Sunyang et al. · Clin Lymphoma Myeloma Leuk · 2021
PMID: 32863193Meta-Analysis
Efficacy and tolerability of mitoxantrone for neuromyelitis optica spectrum disorder: A systematic review.
Enriquez Clare Angeli G, Espiritu Adrian I, Pasco Paul Matthew D · J Neuroimmunol · 2019
PMID: 31005713Meta-Analysis
Therapy-related acute leukaemia with mitoxantrone: four years on, what is the risk and can it be limited?
Ellis Richard, Brown Sean, Boggild Mike · Mult Scler · 2015
PMID: 25013152Meta-Analysis
Mitoxantrone for multiple sclerosis.
Martinelli Boneschi Filippo, Vacchi Laura, Rovaris Marco et al. · Cochrane Database Syst Rev · 2013
PMID: 23728638Meta-AnalysisFull text (PMC)
Mitoxantrone-related acute leukemia in MS: an open or closed book?
Chan Andrew, Lo-Coco Francesco · Neurology · 2013
PMID: 23589639Meta-Analysis
CNOP (mitoxantrone) chemotherapy is inferior to CHOP (doxorubicin) in the treatment of patients with aggressive non-Hodgkin lymphoma (meta-analysis).
Björkholm Magnus, Magnus Björkholm, Andersson Tomas et al. · Eur J Haematol · 2008
PMID: 18331601Meta-Analysis
Mitoxantrone for multiple sclerosis.
Martinelli Boneschi F, Rovaris M, Capra R et al. · Cochrane Database Syst Rev · 2005
PMID: 16235298Meta-Analysis
A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis.
Ghalie R G, Mauch E, Edan G et al. · Mult Scler · 2002
PMID: 12356214Meta-Analysis
[Application of mitoxantrone hydrochloride in lymph node imaging during radical thyroidectomy].
Cheng Y, Zhang S, Liu Z W et al. · Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi · 2024
PMID: 39472118RCT

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Specialists

Providers who commonly manage this intervention

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Mitoxantrone (substance)
SNOMED CT
386913001
UMLS CUI
C0026259
RxNorm CUI
7005

Clinical Data

This intervention maps to 11 entities in the Ltrl knowledge graph.

6
Conditions
3
Biomarkers
1
Specialists
0
Symptoms
9
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.

Mitoxantrone — Conditions, Biomarkers & Specialists | Ltrl | Healos